Skip to main content
$229.50 -$6.24 (-2.6%)

04:00 PM EST on 12/01/21

Biogen Inc (NASDAQ:BIIB)

CAPS Rating: 3 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Current Price $229.50 Mkt Cap $33.7B
Open $236.98 P/E Ratio 22.39
Prev. Close $229.50 Div. (Yield) $0.00 (0.0%)
Daily Range $228.88 - $239.58 Volume 23
52-Wk Range $228.68 - $468.55 Avg. Daily Vol. 1,178,804

Caps

How do you think NASDAQ:BIIB will perform against the market?

Add Stock to CAPS Watchlist

All Players

963 Outperform
75 Underperform
 

All-Star Players

205 Outperform
13 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:BIIB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFAdriaCimino (22.46)
Submitted October 12, 2021

I think Biogen is at a turning point. The company's blockbuster MS revenue is declining. But it has several potential products in phase 3 studies in various treatment areas. I expect Biogen to return to growing revenue and profit as new products come… More

LeakyWallet (< 20)
Submitted July 23, 2021

Seems like the poor testing process control or outright fraud might be systemic within the company - kind of like the pharma version of Boeing MAX.

Recent Community Commentary

Read the most recent pitches from players about BIIB.

Recs

0
Member Avatar TMFSecurity (82.25) Submitted: 11/16/2021 9:09:05 AM : Underperform Start Price: $268.27 NASDAQ:BIIB Score: +10.90

10000000146

Recs

2
Member Avatar TMFAdriaCimino (22.46) Submitted: 10/12/2021 5:54:34 AM : Outperform Start Price: $285.48 NASDAQ:BIIB Score: -23.02

I think Biogen is at a turning point. The company's blockbuster MS revenue is declining. But it has several potential products in phase 3 studies in various treatment areas. I expect Biogen to return to growing revenue and profit as new products come to market.

Recs

2
Member Avatar LeakyWallet (< 20) Submitted: 7/23/2021 5:29:22 PM : Underperform Start Price: $322.10 NASDAQ:BIIB Score: +31.31

Seems like the poor testing process control or outright fraud might be systemic within the company - kind of like the pharma version of Boeing MAX.

Leaderboard

Find the members with the highest scoring picks in BIIB.

Score Leader

optioncoach

optioncoach (90.15) Score: +637.71

The Score Leader is the player with the highest score across all their picks in BIIB.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
fwhittlesey < 20 4/12/2007 Outperform 3Y $43.64 +425.89% +231.38% +194.52 1 Comment
tradersinsights 58.34 4/10/2007 Outperform 1Y $44.42 +416.66% +229.62% +187.04 1 Comment
ambina < 20 3/12/2007 Outperform NS $43.95 +422.18% +239.52% +182.66 0 Comment
anewday101 94.34 3/5/2007 Outperform 1Y $43.36 +429.29% +246.71% +182.58 0 Comment
nickysone 53.94 4/9/2007 Outperform 3Y $44.86 +411.59% +229.30% +182.29 1 Comment
mgroeber < 20 4/9/2007 Outperform NS $44.86 +411.59% +229.30% +182.29 0 Comment
Actionman2go 63.80 4/13/2007 Outperform 3Y $45.00 +410.00% +228.94% +181.06 1 Comment
mtung 39.99 3/8/2007 Outperform NS $44.10 +420.41% +240.26% +180.15 0 Comment
tlop1 < 20 5/18/2007 Outperform 3Y $46.51 +393.44% +213.35% +180.10 0 Comment
apple1jam 67.24 3/6/2007 2/27/2008 Outperform NS $43.94 +422.30% +244.57% +177.73 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BIIB.